Balanced news tone
News Sentiment
BGLC sentiment intelligence
BioNexus Gene Lab Corp Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-10.8% over one week, -15.4% over four weeks, trend inactive, and below fair value.
Brenntag stock holds steady as the chemicals distributor focuses on earnings and portfolio strategy
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
BioNexus Gene Lab Corp. Calls for Malaysia–China
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- GlobeNewswire
BioNexus Gene Lab Corp (BGLC) Slides 4.17% as Support Level Nears – Key Levels to Watch - Gap and Reverse
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- DonanımHaber
BioNexus Gene Lab Corp (BGLC) Slips 3.33% as Stock Tests Key Support at $2.20 - Fibonacci Arc
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
BioNexus Gene Lab Corp (BGLC) Slides 6.25%: Key Support Zone Under Scrutiny - Mid Cap Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- DonanımHaber
BioNexus Gene Lab Corp (BGLC) Slips 3.33% as Stock Tests Key Support at $2.20 - Long Term Entry Picks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
BioNexus Gene Lab Corp (BGLC) Slides 6.25%: Key Support Zone Under Scrutiny - VWAP Breakout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
BioNexus Gene Lab Corp (BGLC) Declines 8.33% as Stock Approaches Key Support - OBV Divergence
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
12 Industrials Stocks Moving In Wednesday's After-Market Session
This article lists 12 industrial stocks that experienced significant movement in Wednesday's after-market session, categorizing them as gainers and losers. Companies like Linkers Industries and Heico saw increases due to factors such as earnings reports, while BioNexus Gene Lab a
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 27 May 2026 19:40
- Source
- Sahm
BioNexus Gene Lab Corp 1Q 2026: Revenue $22.84K, EPS ($0.23) — 10-Q Summary
BioNexus Gene Lab Corp (BGLC) reported its first-quarter 2026 results, showing a significant decline in revenue to $22.84K, a 98.9% decrease year-over-year, while reducing its net loss per share to ($0.23), a 35.2% improvement. The company is actively pivoting its business strate
- Tone
- Negative 36/100
- Event
- Earnings
- Published
- 15 May 2026 21:10
- Source
- TradingView
BioNexus Gene Lab Corp BGLC
This page provides an overview of BioNexus Gene Lab Corp (BGLC) stock performance, showing a closing price of $2.015, a decrease of 2.18%. It includes current market data, a market capitalization of $4.87M, and sections for financials, discussions, and analysis. The platform also
- Tone
- Negative 41/100
- Event
- Market update
- Published
- 12 May 2026 19:09
- Source
- TradingKey
BioNexus Gene Lab (Nasdaq:BGLC) - Stock Analysis
BioNexus Gene Lab (Nasdaq:BGLC) is analyzed with a market cap of US$5.2m. The company's stock has shown significant declines over multiple periods, including a 99.07% drop over five years, and analysts are not currently covering it. There are substantial risks highlighted, such a
- Tone
- Negative 8/100
- Event
- Market update
- Published
- 27 Apr 2026 06:38
- Source
- Simply Wall Street
Why a Fund Made a $3.5 Million Bet on This Flat Chemicals Stock With Declining Revenue and Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- The Motley Fool
BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)
BioNexus Gene Lab reported fiscal-year revenue of $7.42 million, a 21.9% decline due to lower Chemrex volume and foreign exchange. The company also posted a net loss per share of $(1.607) and an 88% increase in operating loss year-over-year. Despite the revenue decline, gross mar
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 14 Apr 2026 21:39
- Source
- TradingView — Track All Markets
BGLC Stock Price, Quote & Chart | BIONEXUS GENE LAB CORP (NASDAQ:BGLC)
BIONEXUS GENE LAB CORP (NASDAQ:BGLC) is currently trading at $2.18, down 3.08% today, and has seen significant declines over longer periods. ChartMill gives BGLC a technical rating of 0/10 and a fundamental rating of 3/10, citing poor profitability but good financial health. The
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 04 Apr 2026 11:09
- Source
- ChartMill
BioNexus Gene Lab (NASDAQ: BGLC) taps new CCO to drive Fidelion VitaGuard MRD commercialization
BioNexus Gene Lab (NASDAQ: BGLC) announced the appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of its affiliate, Fidelion Diagnostics. Dr. Meyyappan will lead Fidelion's global commercial strategy and partnerships for the VitaGuard™ minimal residual disease liquid
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 17 Mar 2026 18:39
- Source
- Stock Titan
Surging Earnings Estimates Signal Upside for Albemarle (ALB) Stock
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- Finviz
Is AngloGold Ashanti PLC (AU) Stock Outpacing Its Basic Materials Peers This Year?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Feb 2026 08:00
- Source
- Market source
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jan 2026 08:00
- Source
- Market source
Is a Stock Market Rotation Underway? These Sectors Are Outpacing Tech in 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jan 2026 08:00
- Source
- Morningstar
About BioNexus Gene Lab Corp.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Dec 2025 08:00
- Source
- ARC Group
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- BioSpace
Stock market news: Senti Biosciences surge by 428.24% while Mondee Holdings plunged by 46.49% during mid day trading
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Dec 2024 08:00
- Source
- Business Upturn
symbol__ Stock Quote Price and Forecast
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 15 Feb 2024 22:23
- Source
- CNN
BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Feb 2024 08:00
- Source
- Sahm
BioNexus Gene Lab (BGLC) Earnings Date and Reports 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Aug 2023 18:25
- Source
- MarketBeat
Should I buy BioNexus Gene Lab Corp. (BGLC)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jul 2023 23:21
- Source
- Zacks Investment Research
BGLC Stock Price and Chart — NASDAQ:BGLC
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jul 2023 18:23
- Source
- TradingView
Bionexus Gene La (BGLC) Stock News & Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jul 2023 17:37
- Source
- Stock Titan